

## FINANCIAL TEAR SHEET

### Corporate Profile

Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the body's own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patient's own T-cells to express our SPEAR TCRs to target and potentially destroy tumors.

Our wholly-owned pipeline includes SPEAR T-cell therapies targeting ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4), and ADP-A2AFP (AFP), which are being investigated in clinical studies across multiple solid tumor indications. We continue to build a pipeline of further proprietary TCR therapeutic candidates, second generation treatment options, as well as allogeneic (off-the-shelf) solutions.

We believe our approach will lead to SPEAR T-cells with the potential to significantly impact cancer treatment and the clinical outcomes of cancer patients.

### Primary IR Contact

Investor Contact

**Email:**

[IR@adaptimmune.com](mailto:IR@adaptimmune.com)

# Stock Performance

## ADAP (AMERICAN DEPOSITARY SHARES)

Exchange	NASDAQ GS (US Dollar)
Price	<b>\$4.94</b>
Change (%)	▲ 0.10 (2.07%)
Volume	223,939
52 Week Low	\$3.60
Market Cap	\$3,099,468,128
Rolling EPS	-0.93
PE Ratio	0
Shares Outstanding	627,422,698

Data as of 02/15/19 4:00 p.m. ET



## Recent Headlines & Events

02/07/19

[Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019](#)

01/07/19

[Dose Escalation in Liver Cancer Study with ADP-A2AFP \(AFP\) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 \(MAGE-A10\) Lung Cancer Study after Favorable Safety Reviews](#)

12/12/18

[Adaptimmune Announces that Gwen Binder will leave in January 2019](#)

DATE	TITLE
02/27/19 8:00 a.m. ET	<a href="#"><u>Adaptimmune Q4 / Full Year 2018 Financial Results and Business Update</u></a>
02/28/19 10:00 a.m. ET	<a href="#"><u>Adaptimmune at 8th Annual Leerink Global Healthcare Conference</u></a> <b>Location</b> Lotte New York Palace 455 Madison Avenue New York, NY 10022

## SEC Filings

## Corporate Governance

<b>FILING DATE</b>	<b>FORM</b>		
02/14/19	<u>SC 13G/A</u>	<u>James Noble</u>	Chief Executive Officer
02/14/19	<u>SC 13G/A</u>	<u>Helen Tayton-Martin, PhD,</u> <u>MBA</u>	Chief Business Officer
01/16/19	<u>4</u>	<u>Rafael Amado, MD</u>	President Research and Development
01/16/19	<u>4</u>	<u>Adrian Rawcliffe</u>	Chief Financial Officer
01/16/19	<u>4</u>	<u>William (Bill) Bertrand</u>	Chief Operating Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.